Novel therapeutic targets for nonalcoholic fatty liver disease

Bibliography

• Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-31
   PubMed Web of Science ®Google Scholar
• Wieckowska A, Feldstein AE. Nonalcoholic fatty liver disease in the pediatric population: a review. Curr Opin Pediatr 2005;17:636-41
   PubMed Web of Science ®Google Scholar
• Brunt EM, Tiniakos DG. Pathological features of NASH. Front Biosci 2005;10:1475-84
   PubMed Web of Science ®Google Scholar
• Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-21
   PubMed Web of Science ®Google Scholar
• Lomonaco R, Sunny NE, Bril F, et al. Nonalcoholic Fatty liver disease: current issues and novel treatment approaches. Drugs 2013;73:1-14
   PubMed Web of Science ®Google Scholar
• Feldstein AE. Novel insights into the pathophysiology of nonalcoholic fatty liver disease. Semin Liver Dis 2010;30:391-401
   PubMed Web of Science ®Google Scholar
• Diehl P, Fricke A, Sander L, et al. Microparticles: major transport vehicles for distinct microRNAs in circulation. Cardiovasc Res 2012;93:633-44
   PubMed Web of Science ®Google Scholar
• Yuan A, Farber EL, Rapoport AL, et al. Transfer of microRNAs by embryonic stem cell microvesicles. PLoS One 2009;4:e4722
   PubMed Web of Science ®Google Scholar
• Morel O, Morel N, Jesel L, et al. Microparticles: a critical component in the nexus between inflammation, immunity, and thrombosis. Semin Immunopathol 2011;33:469-86
   PubMed Web of Science ®Google Scholar
• Rautou PE, Vion AC, Amabile N, et al. Microparticles, vascular function, and atherothrombosis. Circ Res 2011;109:593-606
   PubMed Web of Science ®Google Scholar
• Rautou PE, Bresson J, Sainte-Marie Y, et al. Abnormal plasma microparticles impair vasoconstrictor responses in patients with cirrhosis. Gastroenterology 2012;143:166-76; e6
   PubMedGoogle Scholar
• Witek RP, Yang L, Liu R, et al. Liver cell-derived microparticles activate hedgehog signaling and alter gene expression in hepatic endothelial cells. Gastroenterology 2009;136:320-30; e2
   PubMed Web of Science ®Google Scholar
• Kornek M, Lynch M, Mehta SH, et al. Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis. Gastroenterology 2012;143:448-58
   PubMed Web of Science ®Google Scholar
• Miguet L, Pacaud K, Felden C, et al. Proteomic analysis of malignant lymphocyte membrane microparticles using double ionization coverage optimization. Proteomics 2006;6:153-71
   PubMed Web of Science ®Google Scholar
• Peterson DB, Sander T, Kaul S, et al. Comparative proteomic analysis of PAI-1 and TNF-alpha-derived endothelial microparticles. Proteomics 2008;8:2430-46
   PubMed Web of Science ®Google Scholar
• Prokopi M, Pula G, Mayr U, et al. Proteomic analysis reveals presence of platelet microparticles in endothelial progenitor cell cultures. Blood 2009;114:723-32
   PubMedGoogle Scholar
• Berruyer C, Pouyet L, Millet V, et al. Vanin-1 licenses inflammatory mediator production by gut epithelial cells and controls colitis by antagonizing peroxisome proliferator-activated receptor gamma activity. J Exp Med 2006;203:2817-27
   PubMed Web of Science ®Google Scholar
• Povero DEA, Lazic M, Johnson C, et al. Hepatocytes release microparticles during lipotoxicity that have potent pro-angiogenic effects in vitro and in vivo through Vanin-1-dependent internalization. Hepatology 2012;56:251A
   Google Scholar
• Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002;10:417-26
   PubMed Web of Science ®Google Scholar
• Schroder K, Tschopp J. The inflammasomes. Cell 2010;140:821-32
   PubMed Web of Science ®Google Scholar
• Szabo G, Csak T. Inflammasomes in liver diseases. J Hepatol 2012;57:642-54
   PubMed Web of Science ®Google Scholar
• Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001;2:675-80
   PubMed Web of Science ®Google Scholar
• Seki E, Brenner DA. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 2008;48:322-35
   PubMed Web of Science ®Google Scholar
• Nagy LE. Recent insights into the role of the innate immune system in the development of alcoholic liver disease. Exp Biol Med (Maywood) 2003;228:882-90
   PubMed Web of Science ®Google Scholar
• Farrell GC, van Rooyen D, Gan L, et al. NASH is an Inflammatory Disorder: pathogenic, Prognostic and Therapeutic Implications. Gut Liver 2012;6:149-71
   PubMed Web of Science ®Google Scholar
• Kitazawa T, Tsujimoto T, Kawaratani H, et al. Therapeutic approach to regulate innate immune response by Toll-like receptor 4 antagonist E5564 in rats with D-galactosamine-induced acute severe liver injury. J Gastroenterol Hepatol 2009;24:1089-94
   PubMed Web of Science ®Google Scholar
• Kalil AC, Sun J. Low-dose steroids for septic shock and severe sepsis: the use of Bayesian statistics to resolve clinical trial controversies. Intensive Care Med 2011;37:420-9
   PubMedGoogle Scholar
• Oregui A, Culberson C, Norris E, et al. A TLR4 antagonist decreases hepatic inflammation in response to endotoxin in fatty livers [abstract 1419]. Hepatology 2012;56:859A
   Google Scholar
• Ganz M, Csak T, Nath B, et al. Lipopolysaccharide induces and activates the Nalp3 inflammasome in the liver. World J Gastroenterol 2011;17:4772-8
   PubMed Web of Science ®Google Scholar
• Petrasek J, Bala S, Csak T, et al. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J Clin Invest 2012;122:3476-89
   PubMed Web of Science ®Google Scholar
• Carr RD, Larsen MO, Winzell MS, et al. Incretin and islet hormonal responses to fat and protein ingestion in healthy men. Am J Physiol Endocrinol Metab 2008;295:E779-84
   PubMedGoogle Scholar
• Herrmann C, Goke R, Richter G, et al. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 1995;56:117-26
   PubMed Web of Science ®Google Scholar
• Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004;287:E199-206
   PubMed Web of Science ®Google Scholar
• Zarrinpar A, Loomba R. Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2012;36:909-21
   PubMed Web of Science ®Google Scholar
• Trauner M, Claudel T, Fickert P, et al. Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis 2010;28:220-4
   PubMed Web of Science ®Google Scholar
• Trauner M, Halilbasic E. Nuclear receptors as new perspective for the management of liver diseases. Gastroenterology 2012;140:1120-5; e1-12
   Google Scholar
• Ma K, Saha PK, Chan L, et al. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 2006;116:1102-9
   PubMed Web of Science ®Google Scholar
• Sinal CJ, Tohkin M, Miyata M, et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000;102:731-44
   PubMed Web of Science ®Google Scholar
• Nguyen TA, Sanyal AJ. Pathophysiology guided treatment of nonalcoholic steatohepatitis. J Gastroenterol Hepatol 2012;27(Suppl 2):58-64
   PubMedGoogle Scholar
• Kawamata Y, Fujii R, Hosoya M, et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem 2003;278:9435-40
   PubMed Web of Science ®Google Scholar
• Maruyama T, Miyamoto Y, Nakamura T, et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun 2002;298:714-19
   PubMed Web of Science ®Google Scholar
• Thomas C, Gioiello A, Noriega L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 2009;10:167-77
   PubMed Web of Science ®Google Scholar
• Bays HE, Goldberg RB, Truitt KE, et al. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med 2008;168:1975-83
   PubMed Web of Science ®Google Scholar
• Fonseca VA, Rosenstock J, Wang AC, et al. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 2008;31:1479-84
   PubMed Web of Science ®Google Scholar
• Goldberg RB, Fonseca VA, Truitt KE, et al. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 2008;168:1531-40
   PubMed Web of Science ®Google Scholar
• Hofmann AF. Bile acid sequestrants improve glycemic control in type 2 diabetes: a proposed mechanism implicating glucagon-like peptide 1 release. Hepatology 2011;53:1784
   PubMed Web of Science ®Google Scholar
• Patterson E, Wall R, Fitzgerald GF, et al. Health implications of high dietary omega-6 polyunsaturated Fatty acids. J Nutr Metab 2012;2012:539426
   PubMedGoogle Scholar
• Pettinelli P, Del Pozo T, Araya J, et al. Enhancement in liver SREBP-1c/PPAR-alpha ratio and steatosis in obese patients: correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion. Biochim Biophys Acta 2009;1792:1080-6
   PubMed Web of Science ®Google Scholar
• Cortez-Pinto H, Jesus L, Barros H, et al. How different is the dietary pattern in non-alcoholic steatohepatitis patients? Clin Nutr 2006;25:816-23
   PubMed Web of Science ®Google Scholar
• Musso G, Gambino R, De Michieli F, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003;37:909-16
   PubMed Web of Science ®Google Scholar
• Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol 2007;47:711-17
   PubMed Web of Science ®Google Scholar
• Puri P, Baillie RA, Wiest MM, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007;46:1081-90
   PubMed Web of Science ®Google Scholar
• Puri P, Wiest MM, Cheung O, et al. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology 2009;50:1827-38
   PubMed Web of Science ®Google Scholar
• Parker HM, Johnson NA, Burdon CA, et al. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012;56:944-51
   PubMed Web of Science ®Google Scholar
• Ramsden CE, Ringel A, Feldstein AE, et al. Lowering dietary linoleic acid reduces bioactive oxidized linoleic acid metabolites in humans. Prostaglandins Leukot Essent Fatty Acids 2012;87:135-41
   PubMedGoogle Scholar
• Rivera CA, Adegboyega P, van Rooijen N, et al. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol 2007;47:571-9
   PubMed Web of Science ®Google Scholar
• Spruss A, Kanuri G, Wagnerberger S, et al. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 2009;50:1094-104
   PubMed Web of Science ®Google Scholar
• Miura K, Kodama Y, Inokuchi S, et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology 2010;139:323-34.e7
   PubMed Web of Science ®Google Scholar
• Miura K, Yang L, van Rooijen N, et al. TLR2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation. Hepatology 2013;57(2):577-89
   PubMed Web of Science ®Google Scholar
• Vijay-Kumar M, Aitken JD, Carvalho FA, et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010;328:228-31
   PubMed Web of Science ®Google Scholar